Tibet Rhodiola Pharmaceutical Holding Co (600211) — Cash Flow Quality Index
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Cash Flow Quality Index of 1.38x as of December 2025. Operating cash flow of CN¥297.86 Million exceeds net income of CN¥216.15 Million, indicating high earnings quality where cash backs reported profits. Explore Tibet Rhodiola Pharmaceutical Holding Co long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Tibet Rhodiola Pharmaceutical Holding Co Cash Flow Quality Index (1999–2025)
Historical Cash Flow Quality Index for Tibet Rhodiola Pharmaceutical Holding Co across 25 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 600211 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Year-by-year earnings quality comparison for Tibet Rhodiola Pharmaceutical Holding Co. For live market cap and the full company financial profile, see Tibet Rhodiola Pharmaceutical Holding Co market cap and net worth.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.09x | CN¥1.03 Billion | CN¥937.93 Million | ▲ +16.3% |
| 2024 | 0.94x | CN¥994.79 Million | CN¥1.06 Billion | ▼ -30.3% |
| 2023 | 1.35x | CN¥1.08 Billion | CN¥800.91 Million | ▼ -39.4% |
| 2022 | 2.23x | CN¥837.38 Million | CN¥375.28 Million | ▲ +29.7% |
| 2021 | 1.72x | CN¥366.53 Million | CN¥213.03 Million | ▲ +69.0% |
| 2020 | 1.02x | CN¥428.17 Million | CN¥420.66 Million | ▼ -34.0% |
| 2019 | 1.54x | CN¥489.59 Million | CN¥317.37 Million | ▲ +16.3% |
| 2018 | 1.33x | CN¥289.22 Million | CN¥218.09 Million | ▲ +239.7% |
| 2017 | 0.39x | CN¥91.46 Million | CN¥234.29 Million | ▼ -68.9% |
| 2016 | 1.25x | CN¥250.21 Million | CN¥199.40 Million | ▼ -15.0% |
| 2015 | 1.48x | CN¥133.93 Million | CN¥90.74 Million | ▲ +121.1% |
| 2014 | -7.00x | CN¥-141.40 Million | CN¥20.21 Million | ▼ -160.0% |
| 2013 | 11.65x | CN¥279.22 Million | CN¥23.96 Million | ▲ +532.5% |
| 2012 | 1.84x | CN¥56.20 Million | CN¥30.50 Million | ▲ +221.3% |
| 2011 | 0.57x | CN¥12.09 Million | CN¥21.09 Million | ▲ +629.7% |
| 2010 | 0.08x | CN¥1.90 Million | CN¥24.18 Million | ▼ -90.8% |
| 2009 | 0.86x | CN¥17.88 Million | CN¥20.84 Million | ▼ -76.6% |
| 2008 | 3.66x | CN¥21.46 Million | CN¥5.86 Million | ▼ -73.3% |
| 2006 | 13.70x | CN¥33.63 Million | CN¥2.46 Million | ▲ +205.3% |
| 2004 | 4.49x | CN¥26.90 Million | CN¥6.00 Million | ▼ -45.9% |
| 2003 | 8.30x | CN¥47.20 Million | CN¥5.69 Million | ▲ +156.3% |
| 2002 | 3.24x | CN¥32.85 Million | CN¥10.14 Million | ▲ +281.7% |
| 2001 | 0.85x | CN¥15.47 Million | CN¥18.24 Million | ▲ +47.5% |
| 2000 | 0.58x | CN¥20.55 Million | CN¥35.72 Million | ▲ +747.0% |
| 1999 | 0.07x | CN¥2.25 Million | CN¥33.08 Million | — |